Key result
Treatment with PGE1, PGI2 analogue, and TXA2 blockade significantly improved reduced red cell deformability in patients with peripheral vascular diseases (p<0.01 for all treatments).
Why the study?
Do prostanoids (PGE1, PGI2 analogue, TXA2 blockade) improve red cell deformability in patients with peripheral vascular diseases?
Do prostanoids (PGE1, PGI2 analogue, TXA2 blockade) improve red cell deformability in patients with peripheral vascular diseases?
Answers are grounded in this paper and cite their sources.
Prostanoids (PGE1, PGI2 analogue, and TXA2 blockade) significantly improve reduced red cell deformability in patients with peripheral vascular diseases, suggesting a beneficial role in maintaining microcirculation.
Red cell deformability was measured from the red cell filtration rate (RFR) in the patients of peripheral vascular diseases, using a 5μm Nuclepore microfilter and 20% Ht red cell suspension.In the patients of ASO, TAO and Raynaud's syndrome, the red cell deformability was cleared to be reduced significantly, comparing with age-matched controls.Furthermore, the effects of PGE1, PGI2 analogue (OP-41483) and TXA2 blockade (OKY-046) on red cell deformability in peripheral vascular disease patients were studied.PGE1 was given intravenously 11 patients (80-120μg/day, 5-14 days), and reduced red cell deformability (23.8μl/sec) was improved (47.1μl/sec) significantly (p<0.01).PGI2 analogue was also given to 16 patients (20μg, 40min) intravenously, and pre-treated value was 37.9μl/sec, while post-treated value increased to 48.8μl/sec (p<0.01).TXA2 blockade was given orally (600mg/day, 6 weeks) to 13 patients and red cell deformability was improved significantly (from 46.5 to 58.8μl/sec, p<0.01).The study showed that PGE1, PGI2 and TXA2 blockade were significantly effective on reduced red cell deformability, besides the effectiveness as an anti-platelet agent and a vasodilating agent.These prostanoids were suggested to play an important role in keeping a good microcirculation in the body.
No takes yet. Share an insight, caveat, or question.
Yamaguchi et al. (1988) studied Peripheral vascular diseases (n=40). Prostanoids (PGE1, PGI2 analogue, TXA2 blockade) vs. Pre-treatment baseline was evaluated on Red cell deformability (red cell filtration rate in µl/sec) for PGE1 (p=<0.01). Treatment with PGE1, PGI2 analogue, and TXA2 blockade significantly improved reduced red cell deformability in patients with peripheral vascular diseases (p<0.01 for all treatments).
Synapse has enriched 10 related papers. Consider them for comparative context: